Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatocellular Carcinoma (Hepatoma) Clear all

Conditions: Hepatocellular Carcinoma
Interventions: Tivozanib, Durvalumab; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Gilbert, Arizona • Duarte, California • Orange, California + 7 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions: thalidomide, doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Cancer
Interventions: TAC-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Underlying Liver Disease, Hepatitis, Fibrosis of Liver, Cirrhosis With Suspicion of Liver Cancer, Lesion on a Prior Ultrasound, CT or Outside MRI
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hepatocellular Carcinoma
Interventions: Radiopharmaceutical 18F-FSPG; Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: oxaliplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Duarte, California

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: dolastatin 10; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Zanzalintinib, Tegavivint; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatocellular Carcinoma
Interventions: MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day, MB07133 1800 mg/m2/day, MB07133 2400 mg/m2/day; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Orange, California

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Liver Cancer
Interventions: biologic sample preservation procedure, medical chart review, Patient interview; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Hepatocellular Carcinoma, Liver Cancer
Interventions: Durvalumab, Zanzalintinib; Drug
Lead sponsor: Amit Mahipal; Other
Eligibility: 19 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HCC - Hepatocellular Carcinoma
Interventions: Social Determinants of Health Program, Patient Navigation; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California

Conditions: Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma
Interventions: HFB301001; Drug
Lead sponsor: HiFiBiO Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more

Conditions: Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Carboplatin, Paclitaxel, Pevonedistat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 419
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more

Conditions: Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cancer
Interventions: NIS793, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Nashville, Tennessee • Salt Lake City, Utah

Conditions: Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: cediranib maleate, oxaliplatin, leucovorin calcium, fluorouracil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Cleveland, Ohio • Columbus, Ohio • Mayfield Heights, Ohio + 3 more

Conditions: Hepatocellular Carcinoma
Interventions: SIRT with Y-90 resin microspheres; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
Interventions: INCB106385, INCMGA00012; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Cancer
Interventions: Carboplatin, Cisplatin, Sorafenib; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Liver Cancer, Liver Tumor, Hepatocellular Carcinoma, Hilar Cholangiocarcinoma
Interventions: Not listed
Lead sponsor: Florida Hospital Tampa Bay Division; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions: CEA RNA-pulsed DC cancer vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Oxaliplatin in Treating Patients With Liver Cancer

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

Y-90 Treatment Response Using Transarterial Radioembolization

National Registry and Blood Bank of Patients With Liver Cancer

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Social Determinants of Health HCC Trial

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)

Biological Therapy in Treating Patients With Metastatic Cancer